Researchers demonstrated that the combination of biodegradable nanoparticles encapsulating rapamycin and an engineered Treg-selective IL-2 variant increased the number and durability of total Tregs, as well as induced a profound synergistic increase in antigen-specific Tregs when combined with a target antigen.
[Journal Of Autoimmunity]